EATG » News

EATG is concerned by the Cochrane review of DAA treatment against HCV infection

Direct acting agents used against hepatitis C infection are clinically effective and reliable. EATG, the pan-European network of communities of people living with and affected by hepatitis C (HCV) and…

EATG joins new coalition calling on EU to take action to eliminate viral hepatitis by 2030

Launched at an event in the European Parliament on 7 June 2017, the ACHIEVE (short for Associations Collaborating on Hepatitis to Immunize and Eliminate the Viruses in Europe) coalition calls…

EATG Tuberculosis Team met Belgian Senate

  On May 15, EATG and TBpeople, EECA network of people with tuberculosis with support from the Stop TB Partnership, convened a meeting at the Belgian Senate to raise political awareness to…

EUPATI webinar: Guidance for patient involvement in ethical review of clinical trials

EUPATI will host a webinar, Guidance for patient involvement in ethical review of clinical trials on 29 May 2017 from 17:00 to 18:30 CET. For more information about the webinar and how…

HepHIV 2017 Conference call to action and proceedings

The HepHIV 2017 Conference: HIV and Viral Hepatitis: Challenges of Timely Testing and Care was held by HIV in Europe, in collaboration with European stakeholders, from 31 January - 2…

EmERGE newsletter, May 2017

EmERGE is a project funded by the European Union’s Horizon 2020 Research and Innovation Programme. EmERGE will develop a mHealth platform to enable self-management of HIV in patients with stable disease.…

Stephan Dressler’s presentation on hepatitis B treatment

EATG held an interesting and successful ECAB meeting on viral hepatitis treatment and research in Tbilisi, Georgia in December 2016. The report on the meeting was published previously. This presentation…

ECDC Malta Conference Report Now Out

ECDC has announced on 04/05/2017 the finalisation and  and publication of the notes of the important Malta Presidency HIV Conference (Fast-tracking the end of AIDS in Europe – practical evidence-based interventions) held…

CoPE – Special Round of Applications! Apply Now!

We are pleased to announce a special call for CoPE applications, addressing the specific needs of migrant communities in the European and Central Asian region. This call supports the translation…

Hepatitis C Civil Society Declaration launched

At the Hepatitis C Community Summit held on 18-19 April 2017 in Amsterdam, civil society and community organisations from all over Europe launched a declaration to address the urgent need…

EATG is hiring! Executive Assistant position

EATG is looking for an Executive Assistant (EA). The EA will assist the Executive Director and lead the EATG team in its administrative functions. S/he will organize and supervise the…

Do you want to become an EATG intern?

EATG is looking for an intern to support our project based work and office related work. The intern will assist other staff members in their work, but will also get…

Open letter to Gilead Sciences about PrEP by EATG and PrEP in Europe Initiative

Please read and share the letter signed by EATG, as Europe’s transnational HIV treatment and prevention advocacy group, and the PrEP in Europe Initiative (PEI), a partnership of European prevention and…

Ageing with HIV conference follow-up webinar online

The recording from the Ageing with HIV webinar held on 30 March 2017 is now available online:https://www.ageingwithhiv.com/webinars. The webinar is presented by four young persons who attended the Phase 2 conference ‘New…

Interview with Andrej Senih at the Policy Working Group meeting

In this interview, EATG Policy Working Group chair Andrej Senih discusses the topics and outcomes of the meeting the PWG had on 17-18 March 2017. He also explains the significance…

EATG + TAG webinar on tuberculosis treatment is now online

On 13th March 2017, European AIDS Treatment Group and Treatment Action Group (TAG) have jointly organised a webinar on TB Treatment, with special focus on the treatment of drug resistant and multi-drug…

DON’T MISS THIS – CoPE applications now open!

Call for applications: Continuous Patient Education (CoPE) EATG is pleased to announce that a call for applications for CoPE is now open. Please find below detailed information on how to apply…

Webinar – Ageing with HIV conference outcomes – Children and adolescents

AGEING WITH HIV: Conference outcomes - children & adolescents living with HIV The EATG organised a conference about New challenges and unmet needs of children and adolescents living and ageing…

Sitges IX Meeting on Viral Hepatitis – Report now available

In December 2016, EATG together with Alliance for Public Health Ukraine, Eurasian Harm Reduction Network, and Treatment Preparedness Coalition in EECA (ITPCru) convened a meeting on access to direct-acting antivirals…

EATG + TAG webinar on tuberculosis diagnostics now online

On 6th March 2017, European AIDS Treatment Group and Treatment Action Group (TAG) have jointly organised the webinar on TB Diagnostics. The moderator was Evgenia Maron, leader of the EATG TB…

Fall in HIV among gay men could spell end for Britain’s epidemic, say experts

Public Health England records first downturn in infections in London, thanks to frequent testing and rapid treatment A big drop in the numbers of gay men becoming infected with HIV…

Vaccines can be deemed defective without scientific proof, EU court rules

The medical world has found no causal relationship between hepatitis B vaccines and nervous system diseases such as multiple sclerosis, but the Court of Justice of the European Union (CJEU)…

How six NYC activists changed history with “Silence = Death”

The collective that created the Silence = Death poster is back after thirty years to recall its origins and launch new art. Read the full story published in Village Voice…

HIV-positive women with CMV likelier to pass HIV to infant

UCLA-led study highlights the importance of controlling HIV-infection during pregnancy HIV-positive women with cytomegalovirus (CMV) in their urine at the time of labor and delivery are more than five times…

Update on progress of BIT225 Phase 2 HIV-1 clinical trial

Initial cohort recruited and undergoing treatment. Independent Data and Safety Monitoring Committee unanimously voted to proceed with second, and larger, cohort at a higher dose. Second cohort recruitment and enrolment…

Transplanting kidneys with hepatitis C saves patients’ lives, cures disease

More than 97,000 people in the United States are currently awaiting kidney transplants—waits that can often take five or more years. Two Perelman School of Medicine faculty members recently released…

Is there HIV in my brain?

Joanna Hellmuth, MD, MHS, a neurologist at the University of California, San Francisco, shared information about age- and HIV-related changes to thinking, memory and other cognitive processes. Read the full…

EATG is concerned by the Cochrane review of DAA treatment against HCV infection

Direct acting agents used against hepatitis C infection are clinically effective and reliable. EATG, the pan-European network of communities of people living with and affected by hepatitis C (HCV) and…

WHO to develop Essential Diagnostics List

15 June 2017 - The 20th WHO Model List of Essential Medicines was published on 6 June this year, with a number of important new additions, including a recommendation by…

Historical development of vaginal microbicides

Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes Abstract Infection with human immunodeficiency virus (HIV) remains a global public…

Moving mountains: a surgeon’s fight to legalize HIV-to-HIV organ transplants

Peter Stock, MD, PhD, a transplant surgeon at UC San Francisco, has through his research and advocacy cleared the way for California’s first organ transplants from an HIV-positive donor to…

Three-part series on end-of-life HIV research

In the first of a 3-part series on end-of-life HIV research, Sara Gianella Weibel, MD, on behalf of Infectious Disease Advisor, talks with Davey Smith, MD, professor of medicine and…

HIV has a similar impact to diabetes on heart disease risk

Living with HIV carries the same lifetime risk of cardiovascular disease as having diabetes, even after taking into account smoking, a US study has estimated. The investigators say that more…

Outcomes from a 10 year hepatitis C treatment programme in people who inject drugs

Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response…

Lack of treatment in HBV leads to increased FIB-4 no matter viral load

While patients with hepatitis B who received treatment had a significant initial decline in viral load and little to no change in FIB-4 score, patients with HBV who remained untreated…

Researcher continues progress toward effective HIV inhibitor

Patricia LiWang was at an impasse. It was 2011 and the UC Merced professor’s research group had figured out how to make some of the most potent HIV inhibitors even more…

Study finds fear drives pregnant women with HIV from prevention services

“If my husband leaves me, I will go home and suffer, so better cling to him and hide this thing” A study published June 8, 2017 in PLOS One investigated…

Update on PrEP Impact Trial in England

In response to stakeholders, Public Health England (PHE) and NHS England have published an update on the PrEP Impact Trial. Latest update We continue to make progress preparing for the…

Researchers test best delivery mode for potential HIV vaccine

Knowing HIV levels are ‘undetectable’ may affect sexual behavior

Special JAIDS supplement presents updates from the National HIV Behavioral Surveillance System Understanding and responding to behavioral trends in groups that are at high risk for HIV infection is critical…